An Opinion and Practice Survey on the Structure and Management of Data and Safety Monitoring Boards

Accountability in Research

Volumn 18, Issue 1, 2011, Pages 1-30

  Tereskerz, Patti M ^a   Guterbock, Thomas M ^b   Kermer, Deborah A ^b   Moreno, Jonathan D ^c  

^a UNIVERSITY OF VIRGINIA   (United States)

^b UNIVERSITY OF VIRGINIA   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

data safety monitoring boards

Indexed keywords

ARTICLE; CLINICAL PRACTICE; ETHICS; EVALUATION; EXPERT WITNESS; FEMALE; HUMAN; INFORMATION PROCESSING; MALE; MEDICAL RESEARCH; ORGANIZATION AND MANAGEMENT; PROFESSIONAL STANDARD; QUESTIONNAIRE; STATISTICS; UNITED STATES;

BIOMEDICAL RESEARCH; CLINICAL TRIALS DATA MONITORING COMMITTEES; DATA COLLECTION; ETHICS COMMITTEES, RESEARCH; EXPERT TESTIMONY; FEMALE; HUMANS; MALE; PHYSICIAN'S PRACTICE PATTERNS; QUESTIONNAIRES; UNITED STATES;

EID: 84939548791     PISSN: 08989621     EISSN: 15455815     Source Type: Journal    
DOI: 10.1080/08989621.2011.542680     Document Type: Article

References (22)

1. K.Bolland, and J.Whitehead, 2000. Formal approaches to safety monitoring of clinical trials in life-threatening conditions. Stat. in Med., 19: 2899 – 2917.
2. E.T.Campbell,, S.Regan,, R.L.Gruen,, T.G.Ferris,, R.R.Sowmya,, P.D.Cleary, and D.Blumenthal, 2007. Professionalism in medicine: Results of a national survey of physicians. Ann. Intern. Med., 147: 795 – 802.
3. 21 CFR 312.32(c) (2004).
4. 21 CFR 50.24(a)(7)(iv) (2004).
5. F.Clemens,, D.Elbourne,, J.Darbyshire, and S.Pocock, 2005. DAMOCLES GROUP. Data monitoring in randomized controlled trials: surveys of recent practice and policies. Clin. Trials, 2 (1): 22 – 33.
6. J.F.Collins, 2003. Data and safety monitoring board issues raised in the VA Status Epilepticus Study. Controlled Clinical Trials, 24 (1): 71 – 77.
7. S.M.Cummings,, L.A.Savitz, and T.R.Konrad, 2001. Reported response rates to mailed physician questionnaires. Health Services Research, 35: 1347 – 1355.
8. D.Dillman, 2000. “ Mail and intent questionnaires ”. In The Tailored Design Method, 2nd, John Wiley.
9. D.L.DeMets,, L.Friedman, and C.D.Fuberg, 2005. Data Monitoring in Clinical Trials: A Case Studies Approach, New York: Springer Science Business Media.
10. D.L.DeMets,, S.J.Pocock, and D.G.Julian, 1999. The agonizing negative trend in monitoring of clinical trials. The Lancet, 354: 1983 – 1988.
11. D.O.Dixon, and S.W.Lagakos, 2000. Should data and safety monitoring boards share confidential interim data?. Controlled Clinical Trials, 21 (1): 1 – 6.
12. S.S.Ellenberg,, T.R.Fleming, and D.L.DeMets, 2002. Data Monitoring Committees in Clinical Trials: A Practical Perspective, London: John Wiley & Sons.
13. Food and Drug Administration (FDA). (2006). Guidance for clinical trial sponsors. Establishment and operation of clinical trial data monitoring committees. March 2006 http://www.fda.gov/downloads/RegulatoryInformation/Guidances/ucm127073.pdf (http://www.fda.gov/downloads/RegulatoryInformation/Guidances/ucm127073.pdf)
14. Food and Drug Administration (FDA). (2001). Center for Biologics Evaluation and Research. Open Public Meeting FDA Guidance on Clinical Trial Data Monitoring Committees. Nov. 27, 2001. Transcript available from FDA Web site at http://www.fda.gov (http://www.fda.gov)
15. G.A.M.Kaplan, Gilpin, A. M., J.T.Holbrook,, D.A.Jabs, C.L.Meinert, 2003. Data and safety monitoring board deliberations resulting in the early termination of the monoclonal antibody cytomegalovirus Retinitis Trial. Controlled Clinical Trials, 24 (1): 92 – 98.
16. NIH Guide. NIH Policy for Data and Safety Monitoring http://grants.nih.gov (http://grants.nih.gov) (Accessed: 10 June 1998).
17. NIH Guide. Further Guidance on a Data and Safety Monitoring for Phase I and Phase II Trials. http://grants2.nih.gov (http://grants2.nih.gov) (Accessed: 5 June 2000).
18. A.Slutsky, and J.V.Lavery, 2004. Data safety and monitoring boards. New England Journal of Medicine, 350: 1143 – 1147.
19. J.B.VanGeest,, T.O.Johnson, and V.Welch, 2007. Methodologies for improving response rates in surveys of physicians. Eval. & Health Prof., 30: 303 – 321.
20. J.Whitehead, 1999. On being the statistician on a data and safety monitoring board. Stat. in Med., 18: 3425 – 3434.
21. J.Whitehead, 2000. Monitoring and evaluating clinical trials data. Intensive Care Med., 26: S84 – S 88.
22. D.W.Williams, and T.A.Louis, 2003. DSMB case study: decision making when a similar clinical trial is stopped early. Controlled Clinical Trials, 24 (1): 85 – 91.